Search
Search
Jella An, MD, MBA (Wilmer Eye Institute) Jacob Brubaker, MD (Sacramento Eye Consultants) Ronald M.P.C. de Crom, MD (University Eye Clinic Maastricht) Brian A. Francis, MD, MS (Doheny Eye Institute) Michael C. Giovingo, MD (Cook County Health) Tomás M. Grippo, MD (Grippo Glaucoma and Cataract Center) Brian Jerkins, MD (UT Hamilton Eye Institute) Robert J. Noecker, MD, MBA (OCLI Vision; Yale University) Nathan M. Radcliffe, MD (New York Eye Surgery Center) Marc Töteberg-Harms, MD (USZ Zurich)
Show Description +
An international consensus panel of ten glaucoma experts discussed MicroPulse Transscleral Laser Therapy and their recommendations for dosing and patient selection. The panel executed a complete analysis of the clinical, technical, and practical experience to date and has stepped forward to create a consensus document with recommendations for the worldwide clinical application of MicroPulse TLT. They explained their recommendations for treatment optimization and settings with the revised MicroPulse P3® Probe, the importance of sweep speed, and identified the clinical drivers for patient selection, outcomes, and safety.
Posted: 8/29/2023
Jella An, MD, MBA (Wilmer Eye Institute) Jacob Brubaker, MD (Sacramento Eye Consultants) Ronald M.P.C. de Crom, MD (University Eye Clinic Maastricht) Brian A. Francis, MD, MS (Doheny Eye Institute) Michael C. Giovingo, MD (Cook County Health) Tomás M. Grippo, MD (Grippo Glaucoma and Cataract Center) Brian Jerkins, MD (UT Hamilton Eye Institute) Robert J. Noecker, MD, MBA (OCLI Vision; Yale University) Nathan M. Radcliffe, MD (New York Eye Surgery Center) Marc Töteberg-Harms, MD (USZ Zurich)
An international consensus panel of ten glaucoma experts discussed MicroPulse Transscleral Laser Therapy and their recommendations for dosing and patient selection. The panel executed a complete analysis of the clinical, technical, and practical experience to date and has stepped forward to create a consensus document with recommendations for the worldwide clinical application of MicroPulse TLT. They explained their recommendations for treatment optimization and settings with the revised MicroPulse P3® Probe, the importance of sweep speed, and identified the clinical drivers for patient selection, outcomes, and safety.
Posted: 8/29/2023
Treat and Extend with PASCAL Laser
DIAMONDS: A Randomized Controlled Trial Designed with Patients in Mind
The Clinical and Economic Argument for MicroPulse® Laser in a Retinal Practice
Comprehensive Ophthalmologists Discuss Practice Benefits of Transscleral Laser Therapy (TLT) with MicroPulse® Technology for a Broad Range of Glaucoma Patients
MicroPulse® Transscleral Laser Therapy for the Treatment of Glaucoma: Guidelines from an International Delphi Panel
About Iridex
Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems for the ophthalmology market. The Company’s proprietary MicroPulse technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME), and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors.
Follow Iridex
